| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J Cá. [Incretin hormones]. Vnitrni lekarstvi. vol 57. issue 4. 2011-08-17. PMID:21612069. |
glp-1 receptors have been proved in liver recently but decreased liver glucose production and increased glucose uptake by liver and muscle are mediated indirectly by altering insulin and glucagons levels. |
2011-08-17 |
2023-08-12 |
Not clear |
| S P Shirazi-Beechey, A W Moran, D J Batchelor, K Daly, M Al-Rammah. Glucose sensing and signalling; regulation of intestinal glucose transport. The Proceedings of the Nutrition Society. vol 70. issue 2. 2011-08-09. PMID:21450125. |
gip and glp-1 increase insulin secretion, while glucagon-like peptide 2 (glp-2) modulates intestinal growth, blood flow and expression of sglt1. |
2011-08-09 |
2023-08-12 |
mouse |
| Barbara Huisamen, Amanda Genis, Erna Marais, Amanda Lochne. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovascular drugs and therapy. vol 25. issue 1. 2011-08-03. PMID:21088878. |
other assessments included body weight, intra-peritoneal fat weight, insulin and glp-1 levels as well as histological evaluation of the pancreata. |
2011-08-03 |
2023-08-12 |
human |
| Barbara Huisamen, Amanda Genis, Erna Marais, Amanda Lochne. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovascular drugs and therapy. vol 25. issue 1. 2011-08-03. PMID:21088878. |
they presented with elevated plasma insulin levels and lower glp-1 levels. |
2011-08-03 |
2023-08-12 |
human |
| Barbara Huisamen, Amanda Genis, Erna Marais, Amanda Lochne. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovascular drugs and therapy. vol 25. issue 1. 2011-08-03. PMID:21088878. |
glp-1 levels were elevated and plasma insulin levels lower after treatment. |
2011-08-03 |
2023-08-12 |
human |
| C Gilor, T K Graves, S Gilor, T K Ridge, H-Y Weng, O Dossi. The incretin effect in cats: comparison between oral glucose, lipids, and amino acids. Domestic animal endocrinology. vol 40. issue 4. 2011-08-02. PMID:21397435. |
we aimed to study the incretin effect in cats and to compare the effect of oral glucose, lipids, or amino acids on serum concentrations of insulin, total glucose-dependent insulinotropic peptide (gip) and total glucagon-like peptide 1 (glp-1). |
2011-08-02 |
2023-08-12 |
Not clear |
| C Gilor, T K Graves, S Gilor, T K Ridge, H-Y Weng, O Dossi. The incretin effect in cats: comparison between oral glucose, lipids, and amino acids. Domestic animal endocrinology. vol 40. issue 4. 2011-08-02. PMID:21397435. |
insulin and glp-1 concentrations were positively correlated after glucose (p = 0.001), amino acids (p < 0.001), or lipids (p = 0.001) stimulations. |
2011-08-02 |
2023-08-12 |
Not clear |
| C Gilor, T K Graves, S Gilor, T K Ridge, H-Y Weng, O Dossi. The incretin effect in cats: comparison between oral glucose, lipids, and amino acids. Domestic animal endocrinology. vol 40. issue 4. 2011-08-02. PMID:21397435. |
potentiation of insulin secretion after oral glucose is minimal in cats and is mediated by glp-1 but not gip. |
2011-08-02 |
2023-08-12 |
Not clear |
| R Kodera, K Shikata, H U Kataoka, T Takatsuka, S Miyamoto, M Sasaki, N Kajitani, S Nishishita, K Sarai, D Hirota, C Sato, D Ogawa, H Makin. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. vol 54. issue 4. 2011-08-01. PMID:21253697. |
glucagon-like peptide-1 (glp-1) has various extra-pancreatic actions, in addition to its enhancement of insulin secretion from pancreatic beta cells. |
2011-08-01 |
2023-08-12 |
rat |
| Serenella Salinari, Alessandro Bertuzzi, Geltrude Mingron. Intestinal transit of a glucose bolus and incretin kinetics: a mathematical model with application to the oral glucose tolerance test. American journal of physiology. Endocrinology and metabolism. vol 300. issue 6. 2011-07-29. PMID:21364121. |
the model was then validated by fitting ogtt glucose and glp-1 data in healthy controls and type 2 diabetic patients, and useful information was obtained for the rate of gastric emptying, the rate of glucose absorption, the r(a) profile, the insulin sensitivity, and the glucose effectiveness. |
2011-07-29 |
2023-08-12 |
Not clear |
| Bo Ahré. GLP-1 for type 2 diabetes. Experimental cell research. vol 317. issue 9. 2011-07-18. PMID:21237153. |
glp-1 activates pancreatic receptors resulting in improved glycemia through glucose-dependent stimulation of insulin secretion and inhibition of glucagon secretion. |
2011-07-18 |
2023-08-12 |
human |
| Joan Khoo, Christopher K Rayner, Karen L Jones, Michael Horowit. Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Therapeutics and clinical risk management. vol 5. issue 3. 2011-07-14. PMID:19707284. |
the low risk of hypoglycemia, and beneficial or neutral effects on body weight, render glp-1 agonists and dpp-4 inhibitors suitable alternatives to insulin secretagogues and insulin in overweight and elderly patients. |
2011-07-14 |
2023-08-12 |
Not clear |
| Mahamood Edavalath, Jeffrey W Stephen. Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives. Patient preference and adherence. vol 4. 2011-07-14. PMID:20361006. |
glucagon like peptide-1 (glp-1) is an incretin hormone secreted from the small intestine that lowers fasting and postprandial glucose through multiple mechanisms including glucose-dependent insulin secretion, reduction of glucagon secretion, delaying gastric emptying and increased satiety. |
2011-07-14 |
2023-08-12 |
Not clear |
| Jonathan Pinkney, Thomas Fox, Lakshminarayan Ranganat. Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. Therapeutics and clinical risk management. vol 6. 2011-07-14. PMID:20856686. |
however, unlike sulfonylureas, thiazolidinediones, or insulin, all of which lead to significant weight gain, glp-1 receptor agonists uniquely result in long-term weight loss of around 5 kg, and higher doses may enhance this further. |
2011-07-14 |
2023-08-12 |
Not clear |
| Sun Woo Ki. Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus. Korean diabetes journal. vol 34. issue 6. 2011-07-14. PMID:21246005. |
in contrast, hypoglycemia is uncommon with insulin sensitizers and glp-1 analogs, allowing the physician to titrate these drugs to maximum dosage to reduce hba1c levels below 6.0% and they have been shown to preserve β-cell function. |
2011-07-14 |
2023-08-12 |
Not clear |
| Sun Woo Ki. Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus. Korean diabetes journal. vol 34. issue 6. 2011-07-14. PMID:21246005. |
lastly, weight gain is common with sulfonylurea and insulin therapy, whereas glp-1 analogs induce weight loss and offset the weight gain associated with tzds. |
2011-07-14 |
2023-08-12 |
Not clear |
| Sun Woo Ki. Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus. Korean diabetes journal. vol 34. issue 6. 2011-07-14. PMID:21246005. |
a treatment paradigm shift is recommended in which combination therapy is initiated with diet/exercise, metformin (which has antiatherogenic effects and improves hepatic insulin sensitivity), a tzd (which improves insulin sensitivity and preserves β-cell function with proven durability), and a glp-1 analog (which improves β, α-cell function and promotes weight loss) or a dipeptidyl peptidase iv inhibitor in patients with type 2 diabetes mellitus. |
2011-07-14 |
2023-08-12 |
Not clear |
| C K Chakrabort. The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus. Indian journal of pharmacology. vol 40. issue 1. 2011-07-14. PMID:21264154. |
the peptide (glp-1) increases insulin secretion while decreasing that of glucagon in response to rise in plasma glucose in addition to delay of gastric emptying time, reduction of appetite, preservation of beta-cell function, and increase in beta-cell mass all of which will contribute toward lowering of blood sugar in t2dm. |
2011-07-14 |
2023-08-12 |
Not clear |
| Margreet R Olthof, Aimée E van Dijk, Carolyn F Deacon, Robert J Heine, Rob M van Da. Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on incretin hormones. Nutrition & metabolism. vol 8. 2011-07-14. PMID:21299855. |
decaffeinated coffee slightly increased total glp-1 concentration 30 minutes after ingestion (before the ogtt) relative to placebo (2.7 pmol/l, p = 0.03), but this change did not correspond with changes in glucose or insulin secretion. |
2011-07-14 |
2023-08-12 |
Not clear |
| Bo Ahré. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes, metabolic syndrome and obesity : targets and therapy. vol 3. 2011-07-14. PMID:21437074. |
this increases circulating levels of active glp-1, stimulates insulin secretion and inhibits glucagon secretion, which results in lowering of glucose levels and improvement of the glycemic control in patients with type 2 diabetes. |
2011-07-14 |
2023-08-12 |
human |